Oncology Drugs

Fosun International’s recent triple award win isn't just a PR victory. It’s a signal of a meticulously crafted strategy where ESG, AI, and financial resilience converge.

Acrivon's ACR-2316 shows durable responses in lung cancer, moving to the next phase. The trial's design, guided by AI, aligns with new FDA standards.

As Ascentage Pharma preps its mid-year report, we look beyond the balance sheet at the strategic plays and clinical trials fueling its global oncology ambitions.

With a fortified balance sheet and a strategic pivot, OnKure Therapeutics is betting that precision and selectivity will conquer a competitive drug market.

In a strategic play, Archeus Technologies overhauls its advisory board, positioning itself to accelerate its cancer therapy pipeline in the booming RPT market.

After a corporate overhaul and a massive cash infusion, Faeth Therapeutics is pushing its multi-pronged cancer drug PIKTOR toward pivotal clinical data.

IDEAYA Biosciences advances its breakthrough melanoma drug toward FDA review while its $1.24B cash runway fuels a deep pipeline targeting cancer's toughest codes.

Curium's landmark $8 billion acquisition of Lantheus is set to create a global powerhouse in nuclear medicine, reshaping patient care and the competitive landscape.

Karyopharm plans an accelerated FDA filing for its selinexor combo in myelofibrosis. The move hinges on a key surrogate endpoint and a race against competitors.

Karyopharm's stock plummets after a key cancer trial fails, forcing a strategic retreat and a hard pivot toward more promising assets in its pipeline.

As Cellectar Biosciences preps its Q2 report, all eyes are on its cash runway and the immense promise of its targeted cancer therapy platform.

Knight Therapeutics set a high bar in Q1. As it preps its Q2 results, we look at the strategy and market forces that will define its next chapter.

Lantern Pharma's EMA-cleared trial for LP-184 uses a dual-biomarker strategy, targeting a multi-billion dollar market where patient options are scarce.

A new biotech, CORE Biomedicine, armed with Eisai's preclinical assets and a $21M Series A, aims to upend oncology by targeting cancer's 'lineage' identity.

With two blockbuster cancer drugs driving revenue, Syndax's upcoming Q2 report is a critical test of its path to profitability and ambitious pipeline.

FDA clears a pivotal study for Medicus Pharma's SkinJect, a microneedle patch offering new hope for Gorlin Syndrome and a new playbook in biotech strategy.

Radiopharm Theranostics secures crucial funding for its promising oncology pipeline, but a sharp stock drop reveals deep investor concerns about dilution.

A new clinical trial combines two targeted therapies, offering potential hope for kidney cancer patients who have exhausted even the newest treatment options.

A new publication on Oncotelic's Sapu003 isn't just science; it's a critical de-risking event validating a manufacturing and drug delivery platform.

SKNV's exclusive deal for a university-developed therapy shortens precancerous skin treatment to just four days, challenging norms in both patient care and pharmaceutical commercialization.